Athena regulatory update

ATHN met with the FDA to discuss the non-approvable letter for Zanaflex (tizanidine hydrochloride) it received in March. ATHN (South San Francisco) presented summary results of a recently completed double-blind, placebo-controlled, dose-response study evaluating two single doses of Zanaflex in patients with multiple sclerosis. ...